CODX vs. NMTC, COCH, TMDIF, DRIO, OSRH, BDMD, FEMY, VVOS, PETV, and RVP
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include NeuroOne Medical Technologies (NMTC), Envoy Medical (COCH), Titan Medical (TMDIF), DarioHealth (DRIO), OSR (OSRH), Baird Medical Investment (BDMD), Femasys (FEMY), Vivos Therapeutics (VVOS), PetVivo (PETV), and Retractable Technologies (RVP). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs. Its Competitors
NeuroOne Medical Technologies (NASDAQ:NMTC) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.
16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 8.9% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 6.1% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
NeuroOne Medical Technologies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
NeuroOne Medical Technologies has a net margin of -75.41% compared to Co-Diagnostics' net margin of -1,025.45%. Co-Diagnostics' return on equity of -60.16% beat NeuroOne Medical Technologies' return on equity.
In the previous week, NeuroOne Medical Technologies' average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.
NeuroOne Medical Technologies currently has a consensus target price of $1.45, indicating a potential upside of 98.36%. Co-Diagnostics has a consensus target price of $5.50, indicating a potential upside of 2,007.28%. Given Co-Diagnostics' higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than NeuroOne Medical Technologies.
NeuroOne Medical Technologies has higher earnings, but lower revenue than Co-Diagnostics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroOne Medical Technologies beats Co-Diagnostics on 7 of the 12 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 7/7/2025 by MarketBeat.com Staff
Free CODX Stock Alerts